PMC10401838_01
Pathological findings of specimens obtained by percutaneous liver biopsy in cases 1 (A-C) and case 4 (D-F). HE staining (A, D), hepatocyte staining (B, E), and CK19 staining (C, F).
fonc-13-1234113-g001.jpg
PMC10401838_04_fonc-13-1234113-g001.jpg
f1
Endoscopic ultrasound-guided tissue acquisition was performed, and immunohistochemistry revealed atypical cells with bidirectional hepatocellular differentiation, with the expression of hepatocytes, and ductal differentiation, with CK7/CK19 expression, leading to a diagnosis of cHCC-CCA ( Figure 1 ).
Changes in contrast-enhanced CT findings in responders during treatment. Pretreatment with atezolizumab plus bevacizumab in cases 1 (A), 2 (C), and 5 (E). After treatment with atezolizumab plus bevacizumab in cases 1 (B), 2 (D), and 5 (F), in which a partial response was observed.
fonc-13-1234113-g002.jpg
PMC10401838_05_fonc-13-1234113-g002.jpg
f2
Two months later, PR was observed, and the levels of AFP and PIVKA-II had also decreased ( Figures 2E, F ).
PMC10401838_02
Changes in contrast-enhanced CT findings in responders during treatment. Pretreatment with atezolizumab plus bevacizumab in cases 1 (A), 2 (C), and 5 (E). After treatment with atezolizumab plus bevacizumab in cases 1 (B), 2 (D), and 5 (F), in which a partial response was observed.
fonc-13-1234113-g002.jpg
PMC10401838_05_fonc-13-1234113-g002.jpg
f2
Two months later, PR was observed, and the levels of AFP and PIVKA-II had also decreased ( Figures 2E, F ).
PMC10401838_03
PMC10401838_04
Pathological findings of specimens obtained by percutaneous liver biopsy in cases 1 (A-C) and case 4 (D-F). HE staining (A, D), hepatocyte staining (B, E), and CK19 staining (C, F).
fonc-13-1234113-g001.jpg
PMC10401838_04_fonc-13-1234113-g001.jpg
f1
Endoscopic ultrasound-guided tissue acquisition was performed, and immunohistochemistry revealed atypical cells with bidirectional hepatocellular differentiation, with the expression of hepatocytes, and ductal differentiation, with CK7/CK19 expression, leading to a diagnosis of cHCC-CCA ( Figure 1 ).
PMC10401838_05
Changes in contrast-enhanced CT findings in responders during treatment. Pretreatment with atezolizumab plus bevacizumab in cases 1 (A), 2 (C), and 5 (E). After treatment with atezolizumab plus bevacizumab in cases 1 (B), 2 (D), and 5 (F), in which a partial response was observed.
fonc-13-1234113-g002.jpg
PMC10401838_05_fonc-13-1234113-g002.jpg
f2
Two months later, PR was observed, and the levels of AFP and PIVKA-II had also decreased ( Figures 2E, F ).
PMC10401838_06